Conditions: Advanced Malignant Solid Neoplasm; Cholangiocarcinoma; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm
Intervention: Drug: Infigratinib
Sponsors: Sameek Roychowdhury; National Cancer Institute (NCI)
Not yet recruiting
Feeds
13523 items (13523 unread) in 74 feeds
Acinar Cell Carcinoma
(178 unread)
Acinic Cell Carcinoma
(71 unread)
Adenoid Cystic Carcinoma
(271 unread)
Adrenal Gland Cancer
(1132 unread)
Ampulla Of Vater
(127 unread)
Anal Cancer
(1026 unread)
Angiosarcoma
(358 unread)
Appendix Cancer
(230 unread)
Bile Duct Cancer
(1886 unread)
Brain and CNS
(1849 unread)
Carcinoid
(487 unread)
Endocrine/Neuroendocrine
(1365 unread)
Gall Bladder Cancer
(632 unread)
Hemangioendothelioma
(313 unread)
Hepatoblastoma
(197 unread)
Pancreas
(259 unread)
Phyllodes
(156 unread)
PMP and Mucinous Tumors
(147 unread)
Rhabdomyosarcoma
(615 unread)
Sarcoma
(2224 unread)
Trial - Cholangiocarcinoma (53 unread)
-
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Posted: January 17th, 2020, 3:00pm GMT
-
Hepatic Arterial Infusion Chemotherapy With FOLFOX and Bevacizumab Plus Toripalimab Intravenously for Advanced Biliary Tract Cancer
Posted: January 6th, 2020, 3:00pm GMT
Condition: Advanced Biliary Tract Cancer
Intervention: Other: oxaliplatin, 5-fluorouracil and bevacizumab plus Toripalimab
Sponsor: Peking University
Not yet recruiting -
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
Posted: December 26th, 2019, 3:00pm GMT
Condition: Advanced Hepatocellular Carcinoma (HCC)
Interventions: Drug: MGD013 monotherapy; Drug: MGD013 in combination with Brivanib Alaninate
Sponsor: Zai Lab (Shanghai) Co., Ltd.
Not yet recruiting -
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Posted: December 25th, 2019, 3:00pm GMT
Condition: Advanced Biliary Tract Cancer
Intervention: Drug: Toripalimab plus Lenvatinib
Sponsors: Peking Union Medical College Hospital; Shanghai Junshi Biosciences Co., LTD
Not yet recruiting -
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Posted: December 18th, 2019, 3:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: CPI 613; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: University of Michigan Rogel Cancer Center
Not yet recruiting -
Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma
Posted: December 12th, 2019, 3:00pm GMT
Condition: Cholangiocarcinoma, Intrahepatic
Intervention: Procedure: Liver Transplantation
Sponsor: University Health Network, Toronto
Not yet recruiting -
Safety of ABM-1310 Monotherapy in Patients With Advanced Solid Tumors
Posted: December 9th, 2019, 3:00pm GMT
Condition: Advanced Solid Tumor
Intervention: Drug: ABM-1310
Sponsor: ABM Therapeutics, Inc.
Not yet recruiting -
Futibatinib in Patients With Specific FGFR Aberrations
Posted: December 6th, 2019, 3:00pm GMT
Conditions: Advanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myeloid or Lymphoid Neoplasms (MLN)
Intervention: Drug: Futibatinib
Sponsor: Taiho Oncology, Inc.
Not yet recruiting -
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
Posted: November 25th, 2019, 3:00pm GMT
Conditions: Metastatic Cholangiocarcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Cholangiocarcinoma; Unresectable Hepatocellular Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Pevonedistat
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
Posted: November 15th, 2019, 3:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: NUC-1031; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: NuCana plc
Recruiting -
Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors
Posted: November 8th, 2019, 3:00pm GMT
Conditions: Advanced Solid Tumors; NSCLC; Bladder Cancer; HNSCC; Renal Cancer; Melanoma; Anal Cancer; Colorectal Cancer; Cholangiocarcinoma; Gastric Cancer; Hepatocellular Carcinoma
Interventions: Drug: Continue PD-1/PD-L1 Inhibitors treatment; Other: Discontinue PD-1/PD-L1-1 inhibitor
Sponsor: Antoinette J Wozniak
Recruiting -
Study of PF‑06940434 in Patients With Advanced or Metastatic Solid Tumors.
Posted: November 5th, 2019, 3:00pm GMT
Conditions: Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Lung Squamous Cell Carcinoma; Pancreatic Cancer; Bile Duct Cancer; Endometrial Cancer; Melanoma Cancer; Urothelial Cancer
Interventions: Drug: PF-06940434; Drug: PF-06801591
Sponsor: Pfizer
Recruiting -
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
Posted: November 4th, 2019, 3:00pm GMT
Conditions: Gastric Cancer; Bladder Cancer; Squamous Non-small Cell Lung Cancer; Cholangiocarcinoma; Sarcoma; Endometrial Cancer
Intervention: Drug: CPL304110
Sponsors: Celon Pharma SA; National Center for Research and Development, Poland
Recruiting -
A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers
Posted: October 24th, 2019, 2:00pm GMT
Conditions: Gastrointestinal Neoplasms; Cholangiocarcinoma; Pancreatic Neoplasms
Intervention: Drug: BI 905711
Sponsor: Boehringer Ingelheim
Not yet recruiting -
PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
Posted: September 23rd, 2019, 2:00pm GMT
Condition: Cholangiocarcinoma
Interventions: Drug: Fimaporfin and Gemcitabine; Drug: Gemcitabine/Cisplatin chemotherapy
Sponsor: PCI Biotech AS
Recruiting -
Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Posted: August 26th, 2019, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma; Advanced Gallbladder Carcinoma; Advanced Malignant Solid Neoplasm; Metastatic Cholangiocarcinoma; Metastatic Gallbladder Carcinoma; Metastatic Malignant Solid Neoplasm; Refractory Cholangiocarcinoma; Refractory Gallbladder Carcinoma; Refractory Malignant Solid Neoplasm; Stage III Gallbladder Cancer AJCC v8; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Hilar Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Hilar Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIC Hilar Cholangiocarcinoma AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVA Hilar Cholangiocarcinoma AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Stage IVB Hilar Cholangiocarcinoma AJCC v8
Interventions: Drug: Avelumab; Radiation: Hypofractionated Radiation Therapy; Drug: Nedisertib
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC)
Posted: August 26th, 2019, 2:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Interventions: Drug: Bintrafusp alfa; Drug: Placebo; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting -
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
Posted: July 26th, 2019, 2:00pm GMT
Conditions: Neoplasms With Mesothelin Expression; Epithelioid Mesothelioma; Cholangiocarcinoma, Extrahepatic; Adenocarcinoma, Pancreatic
Interventions: Drug: LMB-100; Drug: Tofacitinib; Device: Mesothelin Expression
Sponsor: National Cancer Institute (NCI)
Recruiting -
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Posted: July 1st, 2019, 2:00pm GMT
Condition: Biliary Tract Carcinoma
Interventions: Drug: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin; Drug: Placebo
Sponsor: Merck Sharp & Dohme Corp.
Recruiting -
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
Posted: June 19th, 2019, 2:00pm GMT
Conditions: Glioma; Cholangiocarcinoma; Solid Tumor; IDH Mutation
Interventions: Drug: Olaparib; Drug: Durvalumab
Sponsor: University Health Network, Toronto
Not yet recruiting -
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
Posted: May 6th, 2019, 2:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Biological: 'SMT-NK' Inj (allogeneic Natural Killer cell); Drug: Pembrolizumab Injection [Keytruda]
Sponsor: SMT bio Co., Ltd.
Recruiting -
Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer
Posted: April 9th, 2019, 2:00pm GMT
Conditions: Mesothelioma; Mesothelioma, Malignant; Mesothelioma; Pleura; Mesotheliomas Pleural; Mesothelioma Peritoneum; Cholangiocarcinoma; Cholangiocarcinoma Recurrent; Ovarian Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic
Interventions: Drug: TC-210 T Cells; Drug: fludarabine; Drug: cyclophosphamide; Biological: anti-PD1
Sponsor: TCR2 Therapeutics
Recruiting -
COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable inTrahepatic Cholangiocarcinoma
Posted: April 2nd, 2019, 2:00pm GMT
Conditions: Intrahepatic Cholangiocarcinoma; Radiotherapy; Immunotherapy
Interventions: Combination Product: Radiotherapy+anti-PD-1; Drug: Gemcitabine+cisplatin
Sponsor: Sun Yat-sen University
Recruiting -
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
Posted: March 18th, 2019, 2:00pm GMT
Conditions: Malignant Solid Neoplasm; Refractory Cholangiocarcinoma; Refractory Malignant Solid Neoplasm
Interventions: Drug: Ceralasertib; Drug: Olaparib
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Posted: February 21st, 2019, 3:00pm GMT
Conditions: Melanoma; Cervical Carcinoma; Pancreatic Carcinoma; Triple Negative Breast Cancer; Hepatocellular Carcinoma; Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Nasopharyngeal Carcinoma; Renal Cell Carcinoma; Non-small Cell Lung Carcinoma; Small Cell Lung Carcinoma; Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced or Metastatic Solid Tumors; Prostate Carcinoma; MSI-H; Mismatch Repair Deficiency; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Intrahepatic Cholangiocarcinoma
Interventions: Biological: XmAb®22841; Biological: Pembrolizumab (Keytruda®)
Sponsors: Xencor, Inc.; ICON Clinical Research
Recruiting -
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
Posted: February 7th, 2019, 3:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention: Drug: M7824
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting -
TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers
Posted: February 4th, 2019, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Metastatic Castration Resistant Prostate Cancer; Renal Cell Carcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Squamous Cell Carcinoma of Head and Neck; Triple-Negative Breast Cancer; Urothelial Carcinoma; Cholangiocarcinoma; GastroEsophageal Cancer; Pancreatic Cancer; Sarcoma
Interventions: Drug: Part 1 TPST-1120; Drug: Part 2a TPST-1120 + nivolumab; Drug: Part 2b TPST-1120 + docetaxel; Drug: Part 2c TPST-1120 + cetuximab; Drug: Part 3 TPST-1120; Drug: Part 4a TPST-1120 + nivolumab; Drug: Part 4b TPST-1120 + docetaxel; Drug: Part 4c TPST-1120 + cetuximab
Sponsor: Tempest Therapeutics
Recruiting -
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Posted: January 29th, 2019, 3:00pm GMT
Condition: HER2-expressing Cancers
Intervention: Drug: ZW49
Sponsor: Zymeworks Inc.
Recruiting -
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Posted: January 14th, 2019, 3:00pm GMT
Conditions: Colon Cancer; Pancreatic Cancer; Cholangiocarcinoma; Mestatic Colon Carcinoma; Liver Metastasis
Interventions: Drug: MVT-5873; Procedure: pancreatectomy or hepatectomy
Sponsor: National Cancer Institute (NCI)
Recruiting -
Trial of IRE in Cholangiocarcinoma
Posted: December 7th, 2018, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Device: IRE Device
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting -
Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
Posted: December 5th, 2018, 3:00pm GMT
Condition: Primary Sclerosing Cholangitis (PSC)
Intervention: Device: SpyGlass DS I - II
Sponsor: Boston Scientific Corporation
Recruiting -
A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Posted: September 26th, 2018, 2:00pm GMT
Conditions: Cohort 1a and 1b: Glioma; Cohort 1a and 1b: Glioblastoma Multiforme; Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Solid Tumors With IDH1 Mutations
Interventions: Drug: FT-2102; Drug: Azacitidine; Biological: Nivolumab; Drug: Gemcitabine and Cisplatin
Sponsor: Forma Therapeutics, Inc.
Recruiting -
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
Posted: September 4th, 2018, 2:00pm GMT
Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Incyte Corporation
Recruiting -
Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members
Posted: August 2nd, 2018, 2:00pm GMT
Condition: Gastrointestinal Cancer
Interventions: Other: Surgeon-palliative care team co management; Other: Surgeon team alone management
Sponsors: Stanford University; Patient-Centered Outcomes Research Institute
Recruiting -
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Posted: July 9th, 2018, 2:00pm GMT
Conditions: Resectable Cholangiocarcinoma; Stage IB Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel
Sponsors: Emory University; Celgene
Recruiting -
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
Posted: January 30th, 2018, 3:00pm GMT
Conditions: Cholangiocarcinoma; Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Perihilar; Cholangiocarcinoma, Extrahepatic; Cholangiocarcinoma, Intrahepatic
Intervention: Drug: ABC294640
Sponsor: RedHill Biopharma Limited
Available -
Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma
Posted: December 6th, 2017, 3:00pm GMT
Conditions: Cholangiocarcinoma Non-resectable; Non-metastatic
Interventions: Drug: Gemcitabine-Oxaliplatin Regimen; Procedure: Hepatic intra arterial chemotherapy
Sponsors: University Hospital, Montpellier; Federation Francophone de Cancerologie Digestive
Recruiting -
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Posted: August 15th, 2017, 2:00pm GMT
Conditions: Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Cancer; Cholangiocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer
Interventions: Drug: Entinostat; Drug: Nivolumab
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; Bristol-Myers Squibb
Recruiting -
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
Posted: July 11th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Glioblastoma; Recurrent Cholangiocarcinoma; Recurrent Glioma; Recurrent Malignant Solid Neoplasm; WHO Grade II Glioma; WHO Grade III Glioma
Intervention: Drug: Olaparib
Sponsor: National Cancer Institute (NCI)
Recruiting -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Posted: May 9th, 2017, 2:00pm GMT
Conditions: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma; Esophageal Cancer; Nasopharyngeal Cancer; Ovarian Cancer; Solid Tumors
Intervention: Drug: INCB062079
Sponsor: Incyte Corporation
Recruiting -
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
Posted: May 4th, 2017, 2:00pm GMT
Conditions: Cancer-associated Thrombosis; Esophageal Cancer; Stomach Cancer; Hepatocellular Carcinoma; Pancreatic Cancer; Duodenal Cancer; Esophagogastric Junction Cancer; Malignant Gastrointestinal Stromal Tumor; Ampulla of Vater Cancer; Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)
Interventions: Drug: Rivaroxaban; Drug: Dalteparin; Drug: apixaban
Sponsor: Asan Medical Center
Recruiting -
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Posted: April 13th, 2017, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Liver Cancer; Gallbladder Cancer
Interventions: Biological: Pembrolizumab (MK-3475); Drug: Oxaliplatin; Drug: Capecitabine
Sponsor: National Cancer Institute (NCI)
Recruiting -
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
Posted: April 5th, 2017, 2:00pm GMT
Condition: Neoplasms
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Anetumab ravtansine (BAY94-9343)
Sponsors: Bayer; ImmunoGen, Inc.; MorphoSys AG
Recruiting -
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Posted: February 20th, 2017, 3:00pm GMT
Conditions: Melanoma; Head and Neck Cancer; Lymphoma; Breast Cancer; Pancreatic Cancer; Liver Cancer; Colon Cancer; Lung Cancer; Glioblastoma; Bile Duct Cancer; Ovarian Cancer; Sarcoma; Squamous Cell Carcinoma
Interventions: Drug: INT230-6; Biological: anti-PD-1 antibody; Biological: anti-CTLA-4 antibody
Sponsor: Intensity Therapeutics, Inc.
Recruiting -
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
Posted: September 21st, 2016, 2:00pm GMT
Conditions: Gastric Cancer; Colorectal Cancer; Pancreatic Cancer; Biliary Cancer
Intervention: Biological: AbGn-107
Sponsor: AbGenomics B.V Taiwan Branch
Recruiting -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Posted: July 4th, 2016, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Liver Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Procedure: TACE; Procedure: RFA; Procedure: Cryoablation
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cho
Posted: March 4th, 2016, 3:00pm GMT
Condition: Neoplasm
Intervention: Drug: Erdafitinib
Sponsor: Janssen Research & Development, LLC
Recruiting -
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Posted: December 11th, 2015, 3:00pm GMT
Condition: Advanced Cancer
Intervention: Biological: pembrolizumab
Sponsor: Merck Sharp & Dohme Corp.
Recruiting -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Posted: October 5th, 2015, 2:00pm GMT
Conditions: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor
Intervention: Drug: Entrectinib
Sponsor: Hoffmann-La Roche
Recruiting -
90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Posted: July 31st, 2015, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Medical University of South Carolina
Recruiting -
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Posted: May 30th, 2014, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
Intervention: Drug: BGJ398 (infigratinib)
Sponsor: QED Therapeutics, Inc.
Recruiting -
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Posted: August 2nd, 2013, 2:00pm GMT
Conditions: Colorectal Neoplasms; Gastric Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Pancreas Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting